Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?

Status: Active, not recruiting
Location: See all (2) locations...
Intervention Type: Diagnostic Test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The objectives of this study are (1) to determine the ex vivo neutralizing capacity and the longevity of SARS-CoV-2-specific Ab responses and (2) to measure the memory B-cell responses in a cohort of health care workers (HCW) recovering from severe, mild or asymptomatic infection. By focusing on HCW, a population that is at risk for re-infection during a second epidemic wave, the correlation between nAb levels and protection is investigated.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: Accepts Healthy Volunteers
View:

• Be diagnosed (PCR+) with COVID-19 between March-May 2020

• Be a permanent employee (HCW: nurse, physician, paramedical) of the study hospital

• Agree to complete a short questionnaire and be sampled 4 tubes of heparin whole blood every 3 months over a one-year period

• Have given their informed consent to participate

Locations
Other Locations
Belgium
University Hospital Antwerp
Antwerpen
Jessa Hospital
Hasselt
Time Frame
Start Date: July 31, 2020
Estimated Completion Date: December 2022
Participants
Target number of participants: 150
Treatments
Experimental: antibody response and memory B-cell
Regular blood draws to measure antibody responses and memory B-cell responses Regular swab collection to test for re-infection
Authors
Related Therapeutic Areas
Sponsors
Collaborators: Universiteit Antwerpen, Mensura, Jessa Hospital, Sciensano, University Hospital, Antwerp
Leads: Institute of Tropical Medicine, Belgium

This content was sourced from clinicaltrials.gov

Similar Clinical Trials